Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay.
Pallett, Scott J C Rayment, Michael Heskin, Joseph Mazzella, Andrea Jones, Rachael Mughal, Nabeela Randell, Paul Davies, Gary W Moore, Luke S P
Pallett, Scott J C
Rayment, Michael
Heskin, Joseph
Mazzella, Andrea
Jones, Rachael
Mughal, Nabeela
Randell, Paul
Davies, Gary W
Moore, Luke S P
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2022-08-12
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Monoclonal antibody therapy has been approved for prophylaxis and treatment of severe COVID-19 infection. Greatest benefit appears limited to those yet to mount an effective immune response from natural infection or vaccination, but concern exists around ability to make timely assessment of immune status of community-based patients where laboratory-based serodiagnostics predominate. Participants were invited to undergo paired laboratory-based (Abbott Architect SARS-CoV-2 IgG Quant II chemiluminescent microparticle immunoassay) and lateral flow assays (LFA; a split SARS-CoV-2 IgM/IgG and total antibody test) able to detect SARS-CoV-2 anti-spike antibodies. LFA band strength was compared with CMIA titer by log-linear regression. Two hundred individuals (median age 43.5 years, IQR 30-59; 60.5% female) underwent testing, with a further 100 control sera tested. Both LFA band strengths correlated strongly with CMIA antibody titers (P < 0.001). LFAs have the potential to assist in early identification of seronegative patients who may demonstrate the greatest benefit from monoclonal antibody treatment.
Citation
Pallett SJC, Rayment M, Heskin J, Mazzella A, Jones R, Mughal N, Randell P, Davies GW, Moore LSP. Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay. Diagn Microbiol Infect Dis. 2022 Nov;104(3):115788. doi: 10.1016/j.diagmicrobio.2022.115788. Epub 2022 Aug 12
Type
Article